SCHEMBL2735384

SCHEMBL2735384

Cc1ccc(Cl)c(C)c1NC(=O)c1nc[nH]c1C(=O)Nc1nc2ccccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 9/20 0.47
NPC1 O15118 7/20 0.47
PKM P14618 2/20 0.47
OPRK1 P41145 1/20 0.47
KLF5 Q13887 1/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
MAOB P27338 1/20 0.45
ADORA2A P29274 1/20 0.45
POLB P06746 1/20 0.44
MAPT P10636 2/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
MCL1 Q07820 1/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NFKB1 P19838 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2759975 0.90 SMN1; SMN2 (0.50) SMN1; SMN2HPGDMAPK1RAB9ANPC1
SCHEMBL216809 0.88 RAB9A (0.52) SMN1; SMN2RAB9ANPC1PKMOPRK1
SCHEMBL2735344 0.86 NPC1 (0.52) SMN1; SMN2HPGDMAPK1RAB9ANPC1
SCHEMBL2735283 0.86 SMN1; SMN2 (0.52) SMN1; SMN2HPGDMAPK1RAB9ANPC1
SCHEMBL213366 0.84 RAB9A (0.57) SMN1; SMN2RAB9ANPC1PKMOPRK1
SCHEMBL2759984 0.84 NPC1 (0.53) SMN1; SMN2RAB9ANPC1PKMOPRK1
SCHEMBL2735267 0.83 NPC1 (0.52) SMN1; SMN2HPGDMAPK1RAB9ANPC1
SCHEMBL2735275 0.82 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1PKMOPRK1
SCHEMBL2735345 0.82 RAB9A (0.56) SMN1; SMN2HPGDRAB9ANPC1PKM
SCHEMBL2735268 0.82 GAA (0.65) SMN1; SMN2HPGDMAPK1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 SMN1; SMN2 2516/4885HPGD 3138/4885MAPK1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.